Effect of laropiprant, a PGD2 receptor 1 antagonist, on estradiol and norgestimate pharmacokinetics after oral contraceptive administration in women.

@article{Schwartz2009EffectOL,
  title={Effect of laropiprant, a PGD2 receptor 1 antagonist, on estradiol and norgestimate pharmacokinetics after oral contraceptive administration in women.},
  author={Jules I. Schwartz and Fang Liu and Yinghong Wang and Barnali Pramanik and Amy O. Johnson-Levonas and Maria J Gutierrez and Eseng Lai and John J. Wagner},
  journal={American journal of therapeutics},
  year={2009},
  volume={16 6},
  pages={487-95}
}
Laropiprant is a prostaglandin D2 receptor 1 antagonist that is being developed in combination with niacin for the treatment of dyslipidemia. This randomized clinical study evaluated the effect of laropiprant on the pharmacokinetics of ethinyl estradiol (EE) and norelgestromin (NGMN), the principal circulating metabolite of norgestimate, in healthy women receiving 3 or more months of an oral contraceptive (Ortho Tri-Cyclen; Ortho-McNeil Pharmaceutical, Raritan, NJ), which contains EE and… CONTINUE READING